#lenacapavir

The rollout of lenacapavir (LEN) in Gauteng has faced challenges, with patients in parts of Pretoria being turned away due to delays. It has been two weeks since the initiation of the vaccination program, but access remains limited for some individuals, according to Health-e News.

The Ministry of Health in Uganda has announced the arrival of an additional 19,200 doses of lenacapavir, a long-acting injectable drug for HIV prevention, due to increasing demand. This shipment is expected next month and will primarily be used for administering second injections to individuals already receiving the treatment.

The rollout of lenacapavir in Gauteng has revealed varying levels of readiness among the 360 designated sites, with 133 located in Gauteng. The first week of the program highlighted these differences in preparedness across clinics, according to Health-e News.

Keletso Mkhwanazi shares their experience receiving lenacapavir, a new HIV prevention injection. Experts indicate that while certain populations are at higher risk for HIV, the jab is available to anyone who is eligible. This article was originally published by Health-e News.

The rollout of lenacapavir, a treatment for HIV, is being implemented selectively, raising concerns about who benefits from it and who does not. While lenacapavir was expected to significantly impact the epidemic, the limited geographic distribution highlights issues of access and equity, suggesting that the approach may reflect political decisions rather than a comprehensive strategy to end HIV.